NASDAQ:KYMR Kymera Therapeutics Q3 2026 Earnings Date & Estimates $110.76 -0.09 (-0.08%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$112.48 +1.72 (+1.56%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kymera Therapeutics is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. The conference call is scheduled for October 28, 2026 at 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 29, 2026TimeBefore Market OpensConference Call DateOctober 28, 2026Conference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Kymera Therapeutics in Q3 2026Kymera Therapeutics is expected to post earnings of -$1.27 per share on revenue of $3.10 million. In the same quarter a year earlier Kymera Therapeutics reported -$0.90 per share on revenue of $2.76 million. Kymera Therapeutics last reported on August 5, 2026, posting -$0.62 per share and beating the -$0.7126 consensus estimate. Kymera Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.27Expected Revenue$3.10 millionPrior-Year EPS-$0.90Prior-Year Revenue$2.76 millionExpected Revenue Growth+12.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.62 (Beat by +$0.0926)Last Quarter Revenue$65.00 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Kymera Therapeutics Q3 2026 Earnings FAQ When does Kymera Therapeutics report Q3 2026 earnings? Kymera Therapeutics (NASDAQ:KYMR) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Kymera Therapeutics' Q3 2026 earnings call? Kymera Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Kymera Therapeutics? Analysts expect Kymera Therapeutics to post earnings of -$1.27 per share for Q3 2026. How much revenue is Kymera Therapeutics expected to report? The consensus revenue estimate for Kymera Therapeutics is $3.10 million for Q3 2026. Kymera Therapeutics Earnings HeadlinesKymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday2 hours ago | americanbankingnews.comKymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026October 22 at 4:01 PM | globenewswire.comFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider. | Weiss Ratings (Ad)SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)October 12, 2026 | prnewswire.comRaymond James initiates coverage of Kymera Therapeutics with outperform ratingOctober 9, 2026 | msn.comKymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very SoonOctober 9, 2026 | seekingalpha.comSee More Kymera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kymera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kymera Therapeutics and other key companies, straight to your email. Email Address About Kymera TherapeuticsKymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities. The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses. Kymera’s pipeline has included degraders directed at proteins such as IRAK4, STAT3, and STAT6, with candidates evaluated in clinical or preclinical studies depending on the program. The company continues to use its proprietary platform to identify and develop additional targeted protein degraders. Founded in 2016 and headquartered in the Boston-area biotechnology hub of Massachusetts, Kymera operates as a research-focused company and has advanced its programs through collaborations and clinical development activities. Its work is intended to support the development of medicines for patients in the United States and international markets, although the company’s programs remain centered on research and development rather than a broad portfolio of marketed products.View Kymera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsPalantir's Next Big Test Isn't a Partnership—It's the NumbersKinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings BeatCapital One Earnings: After a Double Beat the Rally Is OnTractor Supply's Q3 Beat Plants the Seeds for a Stock ReboundWD-40 Could Reward Patient Investors—Here's Why Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
